A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
Stopped early · Not applicable
Conditions studied: HIV Infections
In brief
To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the efficacy of these CTLs in helping the immune system to fight HIV. With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the body to recognize HIV more readily and increase immune response against the virus.
Key facts
- Study ID
- NCT00000824
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- Expected to finish
- 2005-06-01
- Last updated by the study team
- 2016-12-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must have:
- HLA A2+.
- Other HLA matching with sibling.
- CD4 count 100-350 cells/mm3.
- No active opportunistic infection or malignancy (other than cutaneous Kaposi's sarcoma).
- Current stable antiviral regimen.
- Normal lab values and chest x-ray.
- Donor siblings must have:
- HLA A2+.
- HIV negativity.
- Good venous access.
- Ability to donate on multiple occasions.
- Negative status for hepatitis B and C.
You may not qualify if…
- Concurrent Medication:
- Excluded:
- Immunomodulators.
- Cytokines.
- Systemic steroids.
- IV pentamidine.
- Investigational drugs.
Where it is running
- Stanford Univ School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.